Direkt zum Inhalt
Merck

HNDG2MAG-36K

Millipore

MILLIPLEX® Human Neurodegenerative Disease Magnetic Bead Panel 2 - Neuroscience Multiplex Assay

The analytes available for this multiplex kit are: α1-Antitrypsin, Complement C4, CRP, MIP-4, PEDF, SAP.

Anmeldenzur Ansicht organisationsspezifischer und vertraglich vereinbarter Preise


About This Item

UNSPSC-Code:
12161503
eCl@ss:
32161000
NACRES:
NA.84

Qualitätsniveau

Speziesreaktivität

human

Hersteller/Markenname

Milliplex®

assay range

accuracy: 84%
(SAP)

accuracy: 88%
(Complement C4)

accuracy: 92%
(α-1-Antitrypsin)

accuracy: 92%
(PEDF)

accuracy: 95%
(MIP-4)

standard curve range: 0.05-200 ng/mL
(PEDF)

standard curve range: 0.10-50 ng/mL
(CRP)

standard curve range: 0.12-500 ng/mL
(SAP)

standard curve range: 0.24-1,000 ng/mL
(α-1-Antitrypsin)

standard curve range: 0.24-1,000 ng/mL
(Complement C4)

standard curve range: 4.88-20,000 ng/mL
(MIP-4)

Methode(n)

multiplexing: suitable

Nachweisverfahren

fluorometric (Luminex xMAP)

Versandbedingung

wet ice

Allgemeine Beschreibung

The MILLIPLEX® Human Neurodegenerative Bead Panel 2 (HNDG2MAG-36K) is to be used for the simultaneous quantification of the following analytes in any combination: α1-Antitrypsin, Complement C4, CRP, MIP-4, PEDF, SAP.

Neurodegenerative disease is a condition characterized by the deterioration of neurons or their myelin sheath over time in the brain and/or spinal cord. These neurons are responsible for such everyday activities as processing sensory information, making decisions, and controlling movement. Because these cells are not easily regenerated, excessive cumulative damage can lead to age-related diseases such as Alzheimer′s and Parkinson′s disease, as well as other conditions such as amyotrophic lateral sclerosis (ALS) and epilepsy. These disorders are devastating and expensive, both on a personal and global level, and as population demographics continue to change, a therapeutic solution is critical. Consequently, research is underway to identify biomarkers that will help scientists not only understand the pathogenesis of neurodegenerative disease, but also identify people with these disorders before the onset of symptoms and potentially provide new therapeutic tools.

Panel Type: Neuroscience

Spezifität

Cross Reactivty
Cross-reactivity between the antibodies and any of the other analytes in this panel is non-detectable or negligible.

Anwendung

  • Analytes: α1-Antitrypsin, Complement C4, CRP, MIP-4, PEDF, SAP
  • Recommended Sample type: serum, plasma and CSF
  • Recommended Sample dilution: 1:2,000 diluted serum/plasma or 1:20 diluted CSF
  • Assay Run Time: Overnight
  • Research Category: Neuroscience
  • Research Subcategory: Alzheimer′s Disease Nervous System

Leistungsmerkmale und Vorteile

Design your multiplex kit by choosing available analytes within this panel.

Verpackung

Everything you need in a single kit.

Lagerung und Haltbarkeit

Recommended storage for kit components is 2 - 8°C.

Sonstige Hinweise

Sensitivity: See kit protocol for individual sensitvities

Rechtliche Hinweise

MILLIPLEX is a registered trademark of Merck KGaA, Darmstadt, Germany

Haftungsausschluss

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Signalwort

Danger

Gefahreneinstufungen

Acute Tox. 4 Dermal - Acute Tox. 4 Inhalation - Acute Tox. 4 Oral - Aquatic Chronic 2 - Eye Dam. 1 - Skin Sens. 1 - STOT RE 2

Zielorgane

Respiratory Tract

Lagerklassenschlüssel

10 - Combustible liquids


Analysenzertifikate (COA)

Suchen Sie nach Analysenzertifikate (COA), indem Sie die Lot-/Chargennummer des Produkts eingeben. Lot- und Chargennummern sind auf dem Produktetikett hinter den Wörtern ‘Lot’ oder ‘Batch’ (Lot oder Charge) zu finden.

Besitzen Sie dieses Produkt bereits?

In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.

Die Dokumentenbibliothek aufrufen

Aziza Al-Rafiah et al.
BioMed research international, 2021, 3081891-3081891 (2021-10-30)
Parkinson's disease (PD) is one of the most common neurodegenerative disorders. Amphetamine addiction may cause serious of psychotic and physical damage to humans. There is some evidence that shows that amphetamine may increase the risk of PD. Thus, this study
Abdul Hye et al.
Alzheimer's & dementia : the journal of the Alzheimer's Association, 10(6), 799-807 (2014-07-12)
The study aimed to validate previously discovered plasma biomarkers associated with AD, using a design based on imaging measures as surrogate for disease severity and assess their prognostic value in predicting conversion to dementia. Three multicenter cohorts of cognitively healthy
Jingjing Zhou et al.
Frontiers in psychiatry, 12, 593710-593710 (2021-06-08)
Objective: The aim of our study was to identify immune- and inflammation-related factors with clinical utility to predict the clinical efficacy of treatment for depression. Study Design: This was a follow-up study. Participants who met the entry criteria were administered

Unser Team von Wissenschaftlern verfügt über Erfahrung in allen Forschungsbereichen einschließlich Life Science, Materialwissenschaften, chemischer Synthese, Chromatographie, Analytik und vielen mehr..

Setzen Sie sich mit dem technischen Dienst in Verbindung.